大行评级｜美银：上调科伦博泰生物目标价至471.5港元 维持“中性”评级

Core Viewpoint - Bank of America Securities has published a report indicating that Kelun-Biotech's core asset SKB264 has made stable progress across multiple indications, leading to an increase in the probability of success for its clinical-stage indications and subsequently raising peak sales estimates for these indications [1] Group 1 - The firm has raised its revenue forecast for the company from 2023 to 2027 by 1% to 6% [1] - The target price for the company has been increased from HKD 340 to HKD 471.5 [1] - The rating remains "Neutral," as the clinical progress of its assets meets expectations, but short-term licensing opportunities are limited [1]